摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,6-dimethyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester | 682757-64-8

中文名称
——
中文别名
——
英文名称
6,6-dimethyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester
英文别名
ethyl 2,4,5,6-tetrahydro-6,6-dimethyl-3-cyclopyrazolecarboxylate;6,6-Dimethyl-1,4,5,6-tetrahydrocyclopentapyrazole-3-carboxylic acid ethyl ester;ethyl 6,6-dimethyl-4,5-dihydro-1H-cyclopenta[c]pyrazole-3-carboxylate
6,6-dimethyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester化学式
CAS
682757-64-8;682757-79-5
化学式
C11H16N2O2
mdl
——
分子量
208.26
InChiKey
GAQOABBNTKQSBU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    366.7±42.0 °C(Predicted)
  • 密度:
    1.138±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    55
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6,6-dimethyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester甲醇sodium hydroxide盐酸 作用下, 以 乙酸乙酯 为溶剂, 反应 2.5h, 以43.6%的产率得到6,6-dimethyl-1,4,5,6-tetrahydrocyclopentapyrazole-3-carboxylic acid
    参考文献:
    名称:
    Pyrrole and pyrazole DAAO inhibitors
    摘要:
    增加D-丝氨酸浓度和减少D-丝氨酸氧化的有毒产物浓度的方法,用于增强学习、记忆和/或认知能力,或用于治疗精神分裂症、阿尔茨海默病、共济失调或神经病性疼痛,或预防神经元功能丧失,这涉及向需要治疗的受试者施用化合物I的治疗有效量,或其药学上可接受的盐或溶剂:其中R1和R2独立地选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5;或R1和R2共同形成一个5、6、7或8-成员的取代或未取代的碳环或杂环基团;X和Y独立地选自O、S、NH和(CR6R7)n;R3为氢、烷基或M+;M为铝、钙、锂、镁、钾、钠、锌离子或其混合物;Z为N或CR4;R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5;R5选自芳基、取代芳基、杂环芳基和取代杂环芳基;R6和R7独立地选自氢和烷基;n为1到6的整数;R1、R2和R4中至少有一个不是氢;X和Y中至少有一个是(CR6R7)n。 D-丝氨酸或环丝氨酸可以与化合物I的共同给药。
    公开号:
    US20050143443A1
  • 作为产物:
    描述:
    ethyl 2-(3,3-dimethyl-2-oxo-cyclopentyl)-2-oxo-acetate 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以71.2%的产率得到6,6-dimethyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid ethyl ester
    参考文献:
    名称:
    Pyrrole and pyrazole DAAO inhibitors
    摘要:
    增加D-丝氨酸浓度和减少D-丝氨酸氧化的有毒产物浓度的方法,用于增强学习、记忆和/或认知能力,或用于治疗精神分裂症、阿尔茨海默病、共济失调或神经病性疼痛,或预防神经元功能丧失,这涉及向需要治疗的受试者施用化合物I的治疗有效量,或其药学上可接受的盐或溶剂:其中R1和R2独立地选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5;或R1和R2共同形成一个5、6、7或8-成员的取代或未取代的碳环或杂环基团;X和Y独立地选自O、S、NH和(CR6R7)n;R3为氢、烷基或M+;M为铝、钙、锂、镁、钾、钠、锌离子或其混合物;Z为N或CR4;R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5;R5选自芳基、取代芳基、杂环芳基和取代杂环芳基;R6和R7独立地选自氢和烷基;n为1到6的整数;R1、R2和R4中至少有一个不是氢;X和Y中至少有一个是(CR6R7)n。 D-丝氨酸或环丝氨酸可以与化合物I的共同给药。
    公开号:
    US20050143443A1
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED BENZIMDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
    申请人:PLAYER Mark R.
    公开号:US20120202856A1
    公开(公告)日:2012-08-09
    The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    本发明涉及苯并咪唑生物,包含它们的药物组合物以及它们在治疗由TRP M8调节的疾病和症状中的应用,例如炎症性疼痛、炎症性过敏症、炎症性过敏性疾病、神经病性疼痛、神经性寒冷触痛、炎症性体部过敏症、炎症性内脏过敏症、受冷加重的心血管疾病和受冷加重的肺部疾病。
  • Azolecarboxamide herbicides
    申请人:Armel Russell Gregory
    公开号:US20060069132A1
    公开(公告)日:2006-03-30
    Compounds of Formula I, and their N-oxides and agriculturally suitable salts, are disclosed which are useful for controlling undesired vegetation and R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , T, U, W, Y and Z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula I and a method for controlling undesired vegetation which involves contacting the vegetation or its environment with an effective amount of a compound of Formula I. Also disclosed are mixtures and compositions comprising a herbicidally effective amount of a compound of Formula Iz wherein J, R 1a , R 1b , R 1c , R 2a , R 2b , R 3 , R 4 , R 5 , T, U, W, Y and Z are as defined in the disclosure; and an effective amount of another herbicide or herbicide safener. Also disclosed is a method for selectively controlling undesired vegetation in a crop that involves contacting the locus of a crop with an effective amount of a compound of Formula Iz and a effective amount of a safener.
    公开了化学式I的化合物及其N-氧化物和适用于农业的盐,其可用于控制不良杂草,其中R1a,R1b,R1c,R2a,R2b,R3,R4,R5,T,U,W,Y和Z如披露所定义。还公开了含有化学式I的化合物的组合物以及一种控制不良杂草的方法,该方法涉及将化合物I与植物或其环境的有效量接触。还公开了混合物和组合物,包括化学式Iz的除草有效量,其中J,R1a,R1b,R1c,R2a,R2b,R3,R4,R5,T,U,W,Y和Z如披露所定义;以及另一种除草剂除草剂安全剂的有效量。还公开了一种用于选择性控制作物中不良杂草的方法,该方法涉及将化学式Iz的有效量和安全剂的有效量与作物的部位接触。
  • Pyrrole and Pyrazole DAAO Inhibitors
    申请人:Fang Q. Kevin
    公开号:US20100016397A1
    公开(公告)日:2010-01-21
    Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.
    增加D-丝氨酸浓度并减少D-丝氨酸氧化产物浓度的方法,以增强学习、记忆和/或认知能力,或治疗精神分裂症、阿尔茨海默病、共济失调或神经病理性疼痛,或预防神经退行性疾病特征性神经元功能损失,包括向需要治疗的受试者施用公式I的化合物或其药学上可接受的盐或溶剂的治疗有效量:其中,R1和R2分别选自氢、卤素、硝基、烷基、酰基、烷基芳基和XYR5;或R1和R2共同形成5、6、7或8成员取代或未取代的碳环或杂环基;X和Y分别选自O、S、NH和(CR6R7)n;R3为氢、烷基或M+;M为铝离子、钙离子离子、离子、钾离子钠离子离子或其混合物;Z为N或CR4;R4选自氢、卤素、硝基、烷基、烷基芳基和XYR5;R5选自芳基、取代芳基、杂芳基和取代杂芳基;R6和R7分别选自氢和烷基;n为1到6的整数;R1、R2和R4中至少有一个不是氢;X和Y中至少有一个是(CR6R7)n。D-丝氨酸或环丝氨酸可以与公式I的化合物一起共同施用。
  • PYRROLE AND PYRAZOLE DAAO INHIBITORS
    申请人:FANG Q. Kevin
    公开号:US20110092559A1
    公开(公告)日:2011-04-21
    Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: wherein R 1 and R 2 are independently selected from hydrogen, halo, nitro, alkyl, acyl, alkylaryl, and XYR 5 ; or R 1 and R 2 , taken together, form a 5, 6, 7 or 8-membered substituted or unsubstituted carbocyclic or heterocyclic group; X and Y are independently selected from O, S, NH, and (CR 6 R 7 ) n ; R 3 is hydrogen, alkyl or M + ; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc ion or a mixture thereof; Z is N or CR 4 ; R 4 is from selected from hydrogen, halo, nitro, alkyl, alkylaryl, and XYR 5 ; R 5 is selected from aryl, substituted aryl, heteroaryl and substituted heteroaryl; R 6 and R 7 are independently selected from hydrogen and alkyl; n is an integer from 1 to 6; at least one of R 1 , R 2 and R 4 is other than hydrogen; and at least one of X and Y is (CR 6 R 7 ) n . D-serine or cycloserine may be coadministered along with the compound of formula I.
    增加D-丝氨酸浓度和减少D-丝氨酸氧化的有毒产物浓度的方法,以增强学习、记忆和/或认知能力,或用于治疗精神分裂症、阿尔茨海默病、共济失调或神经病理性疼痛,或预防神经退行性疾病特征性神经元功能丧失,包括向需要治疗的受试者施用公式I的化合物的治疗有效量,或其药学上可接受的盐或溶剂:其中,R1和R2分别选自氢、卤、硝基、烷基、酰基、烷基芳基和XYR5;或R1和R2一起形成一个5、6、7或8成员的取代或未取代的碳环或杂环基;X和Y分别选自O、S、NH和(CR6R7)n;R3是氢、烷基或M+;M是铝、离子或其混合物;Z是N或CR4;R4选自氢、卤、硝基、烷基、烷基芳基和XYR5;R5选自芳基、取代芳基、杂芳基和取代杂芳基;R6和R7分别选自氢和烷基;n是1到6的整数;R1、R2和R4中至少有一个不是氢;X和Y中至少有一个是(CR6R7)n。D-丝氨酸或环丝氨酸可以与公式I的化合物一起共同施用。
  • Agonist lead identification for the high affinity niacin receptor GPR109a
    作者:Tawfik Gharbaoui、Philip J. Skinner、Young-Jun Shin、Claudia Averbuj、Jae-Kyu Jung、Benjamin R. Johnson、Tracy Duong、Marc Decaire、Jane Uy、Martin C. Cherrier、Peter J. Webb、Susan Y. Tamura、Ning Zou、Nathalie Rodriguez、P. Douglas Boatman、Carleton R. Sage、Andrew Lindstrom、Jerry Xu、Thomas O. Schrader、Brian M. Smith、Ruoping Chen、Jeremy G. Richman、Daniel T. Connolly、Steven L. Colletti、James R. Tata、Graeme Semple
    DOI:10.1016/j.bmcl.2007.06.028
    日期:2007.9
    A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization. (C) 2007 Elsevier Ltd. All rights reserved.
查看更多